Which cannabinoids produce a psychoactive effect?

28/12/2023
A man holding cannabis leaves that contain cannabinoids

Of all the cannabinoids, delta-9-THC has the strongest psychoactive effects: it is the main intoxicating compound in cannabis. Delta-8-THC and the semi-synthetic cannabinoids HHC, THC-P and THC-H also act on the same CB1 receptor in the brain and are intoxicating. CBD, CBG and CBC do not cause a high, human studies mostly found no cannabis-like effects from CBN, and THCV was indistinguishable from placebo in a small trial.

Key facts

Main psychoactive cannabinoid
Delta-9-THC (tetrahydrocannabinol), which activates the CB1 receptor in the brain
Also intoxicating
Delta-8-THC, HHC, THC-P and THC-H; products sold as these are mostly made in laboratories from hemp-derived CBD
Not intoxicating
CBD, CBG and CBC
CBN
Most human studies found no cannabis-like effects (2021 review)
THCV
Subjectively indistinguishable from placebo at 10 mg a day in a pilot trial of 10 men (2016)
Is CBD psychoactive?
It acts in the brain but does not cause a high; the WHO found no signs of abuse or dependence potential in humans (2018)

Which cannabinoids have psychoactive effects, and why?

The high from cannabis comes mainly from cannabinoids that activate the CB1 receptor, a receptor found mostly in the brain and nervous system (Crocq 2020). Delta-9-THC is the plant's main CB1 activator. In the living plant it occurs mostly as THCA, its acid form, which turns into THC when heated (Wang 2016); see What is THCA?

Strictly speaking, "psychoactive" means any substance that acts on the mind, while "intoxicating" means it causes a high. CBD can act in the brain, but it does not intoxicate. That is why many sources now call CBD non-intoxicating rather than non-psychoactive.

Common cannabinoids compared: do they cause a high? (as of October 2026)
Cannabinoid Intoxicating? What the research shows
Delta-9-THC Yes The main psychoactive compound of cannabis; activates CB1
Delta-8-THC Yes Close relative of THC; the plant makes very little, so products are mostly converted from CBD
HHC Yes Semi-synthetic, made from hemp-derived CBD; THC-like effects in preclinical studies
THC-P and THC-H Yes Found in traces in one cannabis variety; THC-P bound CB1 about 33 times more strongly than THC in laboratory tests
THCV Not at the doses tested Indistinguishable from placebo in a pilot trial of 10 men; made some THC effects weaker and others stronger
CBN Mostly no Forms when THC breaks down; most human studies found no cannabis-like effects
CBD No Does not activate CB1; no abuse or dependence potential found in humans
CBG and CBC No Described as non-psychoactive; little research in people

What does THC do in the brain?

THC binds to and activates CB1 receptors, the receptor that researchers cloned in 1990 (Matsuda 1990). These receptors sit on nerve cells and reduce how much signalling substance they release, which changes mood, memory and perception (Crocq 2020).

Typical short-term effects include euphoria and relaxation, an altered sense of time, impaired short-term memory and coordination, a faster heart rate and increased appetite. How strong they are depends on the dose, how THC is taken and the person. In a controlled trial, 10 mg of vaporised THC impaired verbal memory and caused short-lived psychotic symptoms in healthy volunteers (Englund 2023). Read more in What is THC?

Is CBD psychoactive?

CBD does not cause a high. The World Health Organization concluded in 2018 that "in humans, CBD exhibits no effects indicative of any abuse or dependence potential" (WHO 2018). In cell studies, CBD did not activate the CB1 receptor and instead reduced how strongly other compounds activated it (Laprairie 2015).

Does CBD weaken the effects of THC?

The results are mixed. In a 2013 study, healthy volunteers who took 600 mg of CBD before an injection of THC had less paranoia and less memory impairment than those who took placebo (Englund 2013). But in a 2023 randomised trial with 46 infrequent cannabis users, adding up to three times as much CBD as THC to vaporised cannabis did not change THC's effects on memory, psychotic symptoms or any other measure (Englund 2023). CBD therefore cannot be relied on to cancel out a high. For the differences in detail, see CBD vs THC.

Is CBN psychoactive?

CBN (cannabinol) forms when THC breaks down with age and exposure to air. A 2021 review found that most human studies did not show CBN producing cannabis-like effects, and that there was not enough evidence for the sleep claims made for it (Corroon 2021).

Since then, a small trial in 20 adults with insomnia disorder found that a single dose of 30 or 300 mg CBN did not significantly change time spent awake during the night, its main outcome. The higher dose changed some secondary measures, such as self-rated sleep quality, and the authors called for larger, longer trials (Lavender 2026). Read more in What is CBN? and CBD vs CBN.

Is THCV psychoactive?

THCV (tetrahydrocannabivarin) is related to THC but acts differently at the CB1 receptor. In a pilot trial, 10 male cannabis users took 10 mg THCV or placebo daily for five days. THCV was well tolerated and subjectively indistinguishable from placebo. When THC was given on day five, THCV made some of its effects weaker and others stronger. The authors warned that the study was very small (Englund 2016).

Claims that THCV boosts energy or focus have not been tested in controlled trials. Read more in What is THCV?

Are CBG and CBC psychoactive?

No. CBG (cannabigerol) and CBC (cannabichromene) are described as non-psychoactive cannabinoids (ElSohly 2017). They are mostly studied in the laboratory and in animals, and there is little research in people. See What is CBG? and What is CBC?

Are delta-8-THC, HHC, THC-P and THC-H psychoactive?

Yes. Delta-8-THC differs from delta-9-THC only in the position of one double bond. HHC (hexahydrocannabinol) is a hydrogenated form of THC. The large-scale production of HHC starts from hemp-derived CBD, which is converted into a mixture of delta-8- and delta-9-THC and then hydrogenated (Ujváry 2024). Preclinical studies indicate that HHC has THC-like effects, while its effects in people have hardly been studied. In a survey of 521 delta-8-THC users, most reported relaxation and difficulty concentrating, typical signs of a high (Kruger 2022). We explain HHC in more detail in What is HHC? Delta-10 THC is another THC isomer that is made from hemp-derived CBD in a lab.

THC-P (tetrahydrocannabiphorol) and THC-H (tetrahydrocannabihexol) were identified in a medicinal cannabis variety by Italian researchers in 2019 and 2020 (Citti 2019; Linciano 2020). They have longer side chains than THC: seven and six carbon atoms instead of five. In laboratory tests, THC-P bound to the CB1 receptor about 33 times more strongly than THC, and it produced THC-like effects in mice (Citti 2019). The plant contains only traces, so products sold as THC-P or THC-H are made semi-synthetically, and their effects and safety in people have hardly been studied.

Our article on synthetic and natural cannabinoids explains how the two groups differ.

Are psychoactive cannabinoids legal in the UK?

No, most are controlled. Cannabis is a Class B drug under the Misuse of Drugs Act 1971, and THC is controlled with it (Home Office 2024). According to the Advisory Council on the Misuse of Drugs (ACMD), many semi-synthetic cannabinoids, including THC homologues with longer or shorter side chains such as THC-P, are already Class B under the UK's generic definition of cannabinoids. HHC, HHCP and some related compounds were not captured by that definition. In August 2025 the government accepted the ACMD's advice to list them as named Class B drugs and said it would legislate when parliamentary time allows. In May 2026 it confirmed it would also control THCA, the acid form that turns into THC when heated. Until the new rules are in force, the ACMD notes that psychoactive examples fall under the Psychoactive Substances Act 2016 (ACMD 2025).

Pure CBD, as an isolated substance, is not controlled (Home Office 2024). Read more in is CBD legal in the UK?

Can hemp or CBD oil make you high?

Hemp grown for CBD is bred to contain very little THC, and a CBD oil itself does not cause a high. Full-spectrum oils contain natural traces of THC, and broad-spectrum oils are THC-free. We print the THC content of every batch on the label to two decimals. Traces of THC can still matter for drug tests; read Will CBD show up on a drug test? Our oils are cosmetic products for use on the skin.

From our production

We don't sell HHC or any other cannabinoid that intoxicates, and we don't sell THCA products that turn into THC when heated. We test every batch in Switzerland, and we have never had a failed test since 2013.

— Robin Roy Krigslund-Hansen, co-founder and CEO

Frequently asked questions

Which cannabinoids have psychoactive effects?

Delta-9-THC is the main psychoactive cannabinoid in cannabis. Delta-8-THC and the semi-synthetic cannabinoids HHC, THC-P and THC-H are also intoxicating. CBD, CBG and CBC are not, and most human studies found no cannabis-like effects from CBN.

Is CBD psychoactive?

CBD acts in the brain but does not cause a high. A 2018 WHO review found no effects in humans indicating abuse or dependence potential, so CBD is usually described as non-intoxicating.

Does CBD cancel out a THC high?

No. One 2013 study found less THC-induced paranoia after a high dose of CBD, but a 2023 trial found that adding up to three times as much CBD as THC did not change THC's effects.

Is CBN psychoactive?

Mostly not. A 2021 review found that most human studies did not show CBN producing cannabis-like effects. CBN forms when THC breaks down.

Is THCV psychoactive?

Not at the doses tested so far. In a 2016 pilot trial, 10 mg THCV a day was subjectively indistinguishable from placebo. The study had only 10 participants.

Can hemp make you high?

Hemp grown for CBD contains very little THC, and CBD itself does not cause a high. Products sold as HHC, THC-P or delta-8-THC are a different matter: they are intoxicating, even when they are made from hemp.

This article is general information, not medical or legal advice. Formula Swiss CBD oils are cosmetic products for use on the skin and are not intended to diagnose, treat, cure or prevent any disease.

Last reviewed:

Sources

  1. Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci 2020;22(3):223–228. PMID 33162765
  2. Wang M et al. Decarboxylation study of acidic cannabinoids. Cannabis Cannabinoid Res 2016;1(1):262–271. doi:10.1089/can.2016.0020
  3. Matsuda LA et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–564. doi:10.1038/346561a0
  4. Englund A et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology 2023;48(6):869–876. doi:10.1038/s41386-022-01478-z
  5. World Health Organization, Expert Committee on Drug Dependence. Cannabidiol (CBD): critical review report. Geneva, 2018
  6. Laprairie RB et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015;172(20):4790–4805. doi:10.1111/bph.13250
  7. Englund A et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013;27(1):19–27. doi:10.1177/0269881112460109
  8. Corroon J. Cannabinol and sleep: separating fact from fiction. Cannabis Cannabinoid Res 2021;6(5):366–371. doi:10.1089/can.2021.0006
  9. Lavender IG et al. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial. J Sleep Res 2026;35(4):e70284. doi:10.1111/jsr.70284
  10. Englund A et al. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers. J Psychopharmacol 2016;30(2):140–151. doi:10.1177/0269881115615104
  11. ElSohly MA et al. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 2017;103:1–36. doi:10.1007/978-3-319-45541-9_1
  12. Home Office. Drug licensing factsheet: cannabis, CBD and other cannabinoids. GOV.UK, updated 3 October 2024
  13. Advisory Council on the Misuse of Drugs. Semi-synthetic cannabinoids related to tetrahydro-cannabinol and cannabidiol (report, covering letter of 22 May 2025, and government responses of 20 August 2025 and 11 May 2026). GOV.UK
  14. Ujváry I. Hexahydrocannabinol and closely related semi-synthetic cannabinoids: a comprehensive review. Drug Test Anal 2024;16(2):127–161. doi:10.1002/dta.3519
  15. Kruger JS, Kruger DJ. Delta-8-THC: Delta-9-THC's nicer younger sibling? J Cannabis Res 2022;4(1):4. doi:10.1186/s42238-021-00115-8
  16. Citti C et al. A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-tetrahydrocannabiphorol. Sci Rep 2019;9:20335. doi:10.1038/s41598-019-56785-1
  17. Linciano P et al. Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol. Sci Rep 2020;10:22019. doi:10.1038/s41598-020-79042-2
Back to blog

Leave a comment

Please note, comments need to be approved before they are published.

Robin Roy Krigslund-Hansen

Robin Roy Krigslund-Hansen

About the author

Robin Roy Krigslund-Hansen is the co-founder and CEO of Formula Swiss and is responsible for formulation. Since co-founding the company in 2013, he has written about hemp, CBD, and the cannabis industry. His perspective draws on building Formula Swiss, conversations with researchers, and supporting CBD research.

More about Robin Roy Krigslund-Hansen

How we write and check our guides

Related products